PE/TR Anti-Human CD19 Antibody[4G7]

Introducing the PE/TR Anti-Human CD19 Antibody [4G7], a highly advanced and meticulously developed product designed to revolutionize the field of immunology. This antibody, derived from the hybridoma clone 4G7, exhibits exceptional specificity and affinity towards the CD19 antigen, making it an invaluable tool for various research applications.

The PE/TR Anti-Human CD19 Antibody [4G7] is meticulously manufactured using state-of-the-art techniques, ensuring the highest level of purity and consistency. Its exceptional binding capacity to the CD19 antigen enables precise and accurate detection, quantification, and characterization of CD19-expressing cells.

This antibody is conjugated with two distinct fluorochromes, PE (Phycoerythrin) and TR (Texas Red), allowing for simultaneous multi-color flow cytometric analysis. The PE/TR combination provides enhanced flexibility and versatility in experimental design, enabling researchers to explore complex cellular interactions and phenotypic profiles with utmost precision.

The PE/TR Anti-Human CD19 Antibody [4G7] has been extensively validated and proven to deliver reliable and reproducible results across a wide range of sample types, including peripheral blood, bone marrow, and lymphoid tissues. Its exceptional performance and robustness make it an indispensable tool for immunophenotyping, immunohistochemistry, and other related applications.

Furthermore, this antibody exhibits exceptional stability, ensuring long-term storage without compromising its performance. Its user-friendly formulation and clear instructions guarantee ease of use, making it suitable for both experienced researchers and newcomers in the field.

In summary, the PE/TR Anti-Human CD19 Antibody [4G7] represents a cutting-edge solution for immunological research, offering unparalleled specificity, sensitivity, and versatility. With its exceptional performance and reliability, this antibody is poised to revolutionize the way researchers investigate CD19-expressing cells, ultimately advancing our understanding of immunology and contributing to the development of novel therapeutic strategies.